Post-earnings recap
Reported
Wed, Aug 7, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS, Soleno Therapeutics saw a positive stock reaction, rising 2.58%. This increase may reflect investor optimism about the company's future product developments and management's overall confidence. However, the lack of revenue figures and guidance leaves some uncertainty about the company's immediate financial health.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management remains focused on product development and is optimistic about future opportunities. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing efforts to advance their product pipeline.
They expressed confidence in their long-term strategy despite current challenges.